Literature DB >> 24906566

Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells.

Michel Meignan1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24906566     DOI： 10.1007/s00259-014-2815-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  17 in total

1.  Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

Authors:  Paolo G Gobbi; Emilio Bassi; Manuela Bergonzi; Francesco Merli; Chiara Coriani; Emilio Iannitto; Stefano Luminari; Giuseppe Polimeno; Massimo Federico
Journal:  Hematol Oncol       Date:  2012-01-23       Impact factor: 5.271

2.  Reporting interim positron emission tomography in diffuse large B-cell lymphoma: the Zeno's paradox.

Authors:  Michel Meignan
Journal:  Leuk Lymphoma       Date:  2013-11-12

3.  Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Authors:  Cédric Rossi; Salim Kanoun; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Olivier Humbert; Caroline Legouge; Marie Lorraine Chrétien; Jean-Noel Bastie; François Brunotte; René-Olivier Casasnovas
Journal:  J Nucl Med       Date:  2014-02-24       Impact factor: 10.057

4.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Authors:  Salim Kanoun; Cédric Rossi; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Alexandre Cochet; Olivier Humbert; Michel Toubeau; Emmanuelle Ferrant; François Brunotte; René-Olivier Casasnovas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-09       Impact factor: 9.236

5.  (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.

Authors:  Michal Weiler-Sagie; Olga Bushelev; Ron Epelbaum; Eldad J Dann; Nissim Haim; Irit Avivi; Ayelet Ben-Barak; Yehudit Ben-Arie; Rachel Bar-Shalom; Ora Israel
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

6.  Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.

Authors:  Michel Meignan; Myriam Sasanelli; René Olivier Casasnovas; Stefano Luminari; Federica Fioroni; Chiara Coriani; Helene Masset; Emmanuel Itti; Paolo G Gobbi; Francesco Merli; Annibale Versari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

7.  International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

Authors:  Alden A Moccia; Jane Donaldson; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Tamara N Shenkier; Graham W Slack; Brian Skinnider; Randy D Gascoyne; Joseph M Connors; Laurie H Sehn
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

Authors:  King L Tan; David W Scott; Fangxin Hong; Brad S Kahl; Richard I Fisher; Nancy L Bartlett; Ranjana H Advani; Rena Buckstein; Lisa M Rimsza; Joseph M Connors; Christian Steidl; Leo I Gordon; Sandra J Horning; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

10.  Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Authors:  Diane Tseng; Leelanand P Rachakonda; Zheng Su; Ranjana Advani; Sandra Horning; Richard T Hoppe; Andrew Quon; Edward E Graves; Billy W Loo; Phuoc T Tran
Journal:  Radiat Oncol       Date:  2012-01-19       Impact factor: 3.481
View more
  6 in total

Review 1.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 2.  Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography.

Authors:  Michel Meignan; Martin Hutchings; Lawrence H Schwartz
Journal:  Oncologist       Date:  2015-07-14

Review 3.  Current Role of Functional Imaging in the Management of Lymphoma.

Authors:  Bruce D Cheson; Michel Meignan
Journal:  Curr Oncol Rep       Date:  2021-11-04       Impact factor: 5.075

Review 4.  State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.

Authors:  Thomas Carlier; Clément Bailly
Journal:  Front Med (Lausanne)       Date:  2015-03-23

5.  Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Authors:  Salim Kanoun; Ilan Tal; Alina Berriolo-Riedinger; Cédric Rossi; Jean-Marc Riedinger; Jean-Marc Vrigneaud; Louis Legrand; Olivier Humbert; Olivier Casasnovas; François Brunotte; Alexandre Cochet
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

6.  Prognostic Values of Baseline 18F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma.

Authors:  Yeye Zhou; Xiaoyi Zhang; Haifeng Qin; Zixuan Zhao; Jihui Li; Bin Zhang; Shibiao Sang; Yiwei Wu; Shengming Deng
Journal:  Biomed Res Int       Date:  2020-02-25       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.